Results 101 to 110 of about 4,373 (200)

Antibodies against the beta subunit of voltage-dependent calcium channels in Lambert-Eaton myasthenic syndrome

, 1999
International audienceLambert-Eaton myasthenic syndrome is an autoimmune disease that impairs neuromuscular transmission. Several studies suggest that neurotransmitter release is reduced by an immune response directed against the calcium channel complex ...
Raymond, Cécile, Nicole, Martin-Moutot, Machael, Seagar, Delphine, Bichet, Dewaard, Michel, Cecile, Iborra   +5 more
core  

Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.

, 2011
Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular autoimmune disease that has served as a model for autoimmunity and tumour immunology. In LEMS, the characteristic muscle weakness is thought to be caused by pathogenic autoantibodies directed ...
Lang, B., Maarten J Titulaer, Verschuuren, J.J.G.M., Jan JGM Verschuuren, Lang, Bethan, Titulaer, M.J., Titulaer, MJ, Verschuuren, JJ, Lang, B, Bethan Lang   +9 more
core   +1 more source

CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy

Journal of Neuroinflammation
Background Chimeric antigen receptor (CAR) T cell therapy is emerging as a promising approach for B cell-driven neurological autoimmune disorders, particularly those characterized by pathogenic autoantibodies that target key neural structures.
Muzi Wen, Ruoyi Zheng, Hanqing Zhang, Sophia Y. Goldberg, Zhiying Jian, Ye Gao, Ruogu Cheng, Linxin Wen, Yu Zhao, Saad S. Kenderian, Pei Shang   +10 more
doaj   +1 more source

Decoding Multiple Antibody Positivity: Lessons from Paraneoplastic Sensory Ataxia

Annals of Indian Academy of Neurology
Paraneoplastic neurologic syndromes are cancer-associated, immune-mediated neurologic manifestations that may involve any part of the nervous system.
S Sidharth, Ayush Agarwal, Divyani Garg, Anita Mahadevan, Shamim A Shamim, Pranjal Gupta, Divya M Radhakrishnan, Awadh K Pandit, Achal K Srivastava   +8 more
doaj   +1 more source

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

, 2011
AIM: To assess the treatment effects of rituximab in a population of patients with myasthenia gravis and Lambert-Eaton myasthenic syndrome. METHODS: Data on all treated patients in the UK were collected from referring physicians, with full case ...
Hilton-Jones, David, Davies, Nicholas, Rose, M, McConville, John, Hilton-Jones, D, Rose, Michael, McConville, J, Norwood, Fiona, Jungbluth, Heinz; id_orcid, Davies, N, Maddison, P, Farrugia, Maria Elena, Norwood, F, Robb, Stephanie, Robb, S, Maddison, Paul, Farrugia, ME, Jungbluth, H   +17 more
core   +1 more source

Lambert-Eaton Myasthenic Syndrome: A Review of Rare Neuromuscular Disease Related to Paraneoplastic and Autoimmune

Aksona
Highlight: • LEMS is a rare neurological disease with fluctuating symptoms • Delays and misdiagnosis of LEMS disease often occur • The two main pathophysiologies of LEMS are autoimmune and paraneoplastic.
Ichlasul Mahdi Fardhani, Cindy Graciella, Muhammad Isra Rafidin Rayyan   +2 more
doaj   +1 more source

Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report.

, 2013
International audienceLarge granular lymphocytic (LGL) leukemia is an uncommon clonal lymphoproliferative disorder. Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare neuromuscular autoimmune disease caused by pathogenic autoantibodies targeting the ...
Roche, Corinne, Bay, Jacques-Olivier, Chaleteix, Carine, Minard, Patrice, Tournilhac, Olivier, Lamy, Thierry, Lemal, Richard   +6 more
core   +1 more source

Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.

, 2014
Lambert-Eaton myasthenic syndrome (LEMS) is a pre-synaptic disorder of the neuromuscular and autonomic transmission mediated by antibodies to voltage-gated calcium channels at the motor nerve terminal.
Giometto B, A. Evoli, Evoli A, C. Rodolico, I. W. Group, Evoli, Amelia, A. Romani, Vigliani MC, R. Mantegazza, Rodolico C, LIGUORI, ROCCO, Liguori R, M. C. Vigliani, E. Pegoraro, B. Giometto, Romani A, Di Muzio A, Mantegazza R, PEGORARO, ELENA, A. D. Muzio, Pegoraro E   +20 more
core   +1 more source

Walsh & Hoyt: Lambert-Eaton Myasthenic Syndrome

, 2005
A disorder resembling MG in patients with bronchogenic carcinoma was first described by Anderson et al. in 1953, and subsequent investigators reported similar cases.
Preston C. Calvert, MD (retired)
core  

062 Pembrolizumab induced lambert-eaton myasthenic syndrome

BMJ Neurology Open, 2021
Rob Zielinski, Rami Haddad, Jasmine Ashhurst   +2 more
doaj   +1 more source